Nkarta, Inc. (NKTX) company profile
Close on Nov 17, 2026Market cap $89.53MP/E –Yield 0.00%
About Nkarta
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical organization focused on creating allogeneic, off-the-shelf engineered natural killer cell therapies. Its primary pipeline candidate, NKX019, is an engineered chimeric antigen receptor natural killer cell product designed to target the CD19 antigen. This lead candidate aims to treat various autoimmune conditions, including lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, and antineutrophil cytoplasmic antibody-associated vasculitis. It previously evaluated product candidates in oncology indications before redirecting its primary resources toward autoimmune diseases.
The organization operates two current good manufacturing practice facilities situated in South San Francisco, California. These internal facilities supply cell therapy products for ongoing and future clinical trials, with capacity planned to support potential commercial production. Clinical evaluations and investigator-sponsored trials involving its therapies take place across collaborating medical centers and universities within the United States.
Summary of the business section of Nkarta's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nkarta, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 1150 Veterans Boulevard 94080
- Phone
- (925) 407-1049
- Website
- nkartatx.com
- Employees
- 108, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, California
Stock & identifiers
- Ticker
- NKTX
- Exchange
- Nasdaq
- IPO date
- Jul 13, 2020
- Shares outstanding
- 72M, Aug 5, 2026
- Public float
- $82.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1787400
- CUSIP
- 65487U108
- ISIN
- US65487U1088
- FIGI
- BBG00JXHS9G7
- Share class FIGI
- BBG00JXHS9H6
- EIN
- 47-4515206
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul J. Hastings | Chief Executive Officer, Director | 390,247 |
| Nadir Mahmood | President | 167,727 |
| Shawn Marshall Rose | See Remarks | 70,000 |
| Alicia J. Hager | Chief Legal Officer | 146,735 |
| Ralph Brandenberger | Chief Technical Officer | 124,796 |
| Alyssa Levin | See Remarks | 102,662 |
| David Shook | See Remarks | 190,955 |
| Capital Healthcare Fund LP RA | Director | – |
| Zachary Scheiner | Director | – |
| Leone D. Patterson | Director | – |
| Angela Thedinga | Director | – |
| George Vratsanos | Director | – |
| Michael Dybbs | Director | – |
| Rajeev M. Shah | Director | 7,805,129 |
| Peter Kolchinsky | Director | – |
| RA Capital Nexus Fund, L.P. | Director | – |
| Ra Capital Management, L.P. | Director | 10,050,818 |
| Simeon George | Director | 3,333,333 |
| Ali Behbahani | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.98M | $2.04M | $1.31M | $28 | – |
| FY2024 | $3.99M | $1.54M | $2.62M | $38 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Paul J. Hastings Chief Executive Officer | $674.38K | $236.25K | $1.71M | $344.95K | $10.50K | $2.98M | -25% |
| Nadir Mahmood President | $543.25K | $155.00K | $434.65K | $252.61K | $10.50K | $1.40M | -58% |
| Shawn Rose Chief Medical Officer and Head of Research and Development | $316.59K | – | $709.30K | $189.72K | $9.16K | $1.22M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 13, 2020
- Offer price
- $18.00
- Securities offered
- 14,000,000
- Gross proceeds
- $252.00M
- Exchange
- Nasdaq
- First trading day
- Jul 10, 2020
- First-day close
- $47.90+166.1%
- Lock-up ends (est.)
- Jan 6, 2021
“Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “NKTX.” The initial public offering price is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 108 full-time employees, 28 of whom have advanced degrees including but not limited to Ph.D., M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 13, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 2, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?